Cargando…
Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
BACKGROUND: There is a pressing need for improved methods to identify effective therapeutics for diseases. Many computational approaches have been developed to repurpose existing drugs to meet this need. However, these tools often output long lists of candidate drugs that are difficult to interpret,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207828/ https://www.ncbi.nlm.nih.gov/pubmed/37226094 http://dx.doi.org/10.1186/s12859-023-05343-8 |
_version_ | 1785046539782062080 |
---|---|
author | Garana, Belinda B. Joly, James H. Delfarah, Alireza Hong, Hyunjun Graham, Nicholas A. |
author_facet | Garana, Belinda B. Joly, James H. Delfarah, Alireza Hong, Hyunjun Graham, Nicholas A. |
author_sort | Garana, Belinda B. |
collection | PubMed |
description | BACKGROUND: There is a pressing need for improved methods to identify effective therapeutics for diseases. Many computational approaches have been developed to repurpose existing drugs to meet this need. However, these tools often output long lists of candidate drugs that are difficult to interpret, and individual drug candidates may suffer from unknown off-target effects. We reasoned that an approach which aggregates information from multiple drugs that share a common mechanism of action (MOA) would increase on-target signal compared to evaluating drugs on an individual basis. In this study, we present drug mechanism enrichment analysis (DMEA), an adaptation of gene set enrichment analysis (GSEA), which groups drugs with shared MOAs to improve the prioritization of drug repurposing candidates. RESULTS: First, we tested DMEA on simulated data and showed that it can sensitively and robustly identify an enriched drug MOA. Next, we used DMEA on three types of rank-ordered drug lists: (1) perturbagen signatures based on gene expression data, (2) drug sensitivity scores based on high-throughput cancer cell line screening, and (3) molecular classification scores of intrinsic and acquired drug resistance. In each case, DMEA detected the expected MOA as well as other relevant MOAs. Furthermore, the rankings of MOAs generated by DMEA were better than the original single-drug rankings in all tested data sets. Finally, in a drug discovery experiment, we identified potential senescence-inducing and senolytic drug MOAs for primary human mammary epithelial cells and then experimentally validated the senolytic effects of EGFR inhibitors. CONCLUSIONS: DMEA is a versatile bioinformatic tool that can improve the prioritization of candidates for drug repurposing. By grouping drugs with a shared MOA, DMEA increases on-target signal and reduces off-target effects compared to analysis of individual drugs. DMEA is publicly available as both a web application and an R package at https://belindabgarana.github.io/DMEA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-023-05343-8. |
format | Online Article Text |
id | pubmed-10207828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102078282023-05-25 Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing Garana, Belinda B. Joly, James H. Delfarah, Alireza Hong, Hyunjun Graham, Nicholas A. BMC Bioinformatics Research BACKGROUND: There is a pressing need for improved methods to identify effective therapeutics for diseases. Many computational approaches have been developed to repurpose existing drugs to meet this need. However, these tools often output long lists of candidate drugs that are difficult to interpret, and individual drug candidates may suffer from unknown off-target effects. We reasoned that an approach which aggregates information from multiple drugs that share a common mechanism of action (MOA) would increase on-target signal compared to evaluating drugs on an individual basis. In this study, we present drug mechanism enrichment analysis (DMEA), an adaptation of gene set enrichment analysis (GSEA), which groups drugs with shared MOAs to improve the prioritization of drug repurposing candidates. RESULTS: First, we tested DMEA on simulated data and showed that it can sensitively and robustly identify an enriched drug MOA. Next, we used DMEA on three types of rank-ordered drug lists: (1) perturbagen signatures based on gene expression data, (2) drug sensitivity scores based on high-throughput cancer cell line screening, and (3) molecular classification scores of intrinsic and acquired drug resistance. In each case, DMEA detected the expected MOA as well as other relevant MOAs. Furthermore, the rankings of MOAs generated by DMEA were better than the original single-drug rankings in all tested data sets. Finally, in a drug discovery experiment, we identified potential senescence-inducing and senolytic drug MOAs for primary human mammary epithelial cells and then experimentally validated the senolytic effects of EGFR inhibitors. CONCLUSIONS: DMEA is a versatile bioinformatic tool that can improve the prioritization of candidates for drug repurposing. By grouping drugs with a shared MOA, DMEA increases on-target signal and reduces off-target effects compared to analysis of individual drugs. DMEA is publicly available as both a web application and an R package at https://belindabgarana.github.io/DMEA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-023-05343-8. BioMed Central 2023-05-24 /pmc/articles/PMC10207828/ /pubmed/37226094 http://dx.doi.org/10.1186/s12859-023-05343-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Garana, Belinda B. Joly, James H. Delfarah, Alireza Hong, Hyunjun Graham, Nicholas A. Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing |
title | Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing |
title_full | Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing |
title_fullStr | Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing |
title_full_unstemmed | Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing |
title_short | Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing |
title_sort | drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207828/ https://www.ncbi.nlm.nih.gov/pubmed/37226094 http://dx.doi.org/10.1186/s12859-023-05343-8 |
work_keys_str_mv | AT garanabelindab drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing AT jolyjamesh drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing AT delfarahalireza drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing AT honghyunjun drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing AT grahamnicholasa drugmechanismenrichmentanalysisimprovesprioritizationoftherapeuticsforrepurposing |